<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04296097</url>
  </required_header>
  <id_info>
    <org_study_id>38RC18.208</org_study_id>
    <secondary_id>2019-A01562-55</secondary_id>
    <nct_id>NCT04296097</nct_id>
  </id_info>
  <brief_title>Evaluation of Deep Brain Stimulation (DBS) of the Right Operculum 3 (OP3) in Permanent Non-pulsatile Disabling Tinnitus (TINNOP3-DBS)</brief_title>
  <acronym>TINNOP3-DBS</acronym>
  <official_title>Evaluation of Deep Brain Stimulation (DBS) of the Right Operculum 3 (OP3) in Permanent Non-pulsatile Disabling Tinnitus (TINNOP3-DBS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clinatec, COMMISSARIAT À L'ÉNERGIE ATOMIQUE ET AUX ÉNERGIES ALTERNATIVES (CEA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Équipe 5 Neuroimagerie et perfusion cérébrale, Grenoble Institut des Neurosciences (GIN)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot study aims at evaluating the effectiveness of the treatment of unilateral or
      bilateral, non-pulsatile, disabling, tinnitus, without vestibular dysfunction, using Deep
      Brain Stimulation (DBS) of the parieto-insular right operculum 3 (OP3) in a cross-over,
      double study design.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjective, non-pulsatile, permanent, severe, tinnitus, refractory to all treatment are very
      disabling. They can lead to serious depression and suicidal behavior, which justifies the
      development of innovative therapeutic options. Current management is essentially based on
      psychological therapy and / or prosthetic, to improve for hearing loss that can be frequently
      associated. In fact, the main objective is habituation for these patients, but when the
      tinnitus is too intense, it is impossible. Three recent publications in functional magnetic
      resonance imaging (fMRI) have reported a novel physiopathological hypothesis to explain the
      appearance of subjective tinnitus. They highlight the prominent role of the right operculum 3
      (OP3), a deep opercular region (parieto-insular junction) in the emergence of this symptom.
      The investigators hypothesize that inhibition of this region using high frequency stimulation
      could, significantly improve the intensity of the symptom and consequently their quality of
      life in this selected population.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2020</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Deep Brain Stimulation (DBS) of the parieto-insular region at the level of the right operculum 3 (OP3)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Crossover study conducted in double blind design :
one month Deep Brain Stimulation (DBS) ON, 15 days wash out stimulation OFF, and one month Deep Brain Stimulation (DBS) OFF or
one month Deep Brain Stimulation (DBS) OFF, 15 days wash out stimulation OFF, and one month Deep Brain Stimulation (DBS) ON</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Effectiveness of the treatment using Deep Brain Stimulation (DBS) of the right operculum 3 (OP3).</measure>
    <time_frame>2.5 months</time_frame>
    <description>Difference in intensity of tinnitus Visual Analog Scale (VAS) [0/10 : higher scores mean better outcome] between the end and the beginning of each of the two periods of the crossover.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of DBS Treatment on Emergent Adverse Events (Tolerance) after surgical intervention and stimulation following the implantation of the DBS medical device.</measure>
    <time_frame>15 months</time_frame>
    <description>Emergent Adverse events (partial or general epileptic seizures, worsening of tinnitus, surgical complications, ...): 1) post-operative computed tomography (CT); 2) Clinical evaluation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the subjective effect of stimulation on quality of life.</measure>
    <time_frame>15 months</time_frame>
    <description>Scores on the Tinnitus Handicap Inventory (THI) questionnaire [0/100 : higher scores mean worse outcome] at 6 months (early phase) and at 15 months compared to the preoperative THI of the same patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the subjective effect of stimulation on anxiety / depression.</measure>
    <time_frame>15 months</time_frame>
    <description>Scores on the Hospital Anxiety and Depression Scale (HAD) [0/21 : higher scores mean worse outcome] at 6 months (early phase) and at 15 months compared to preoperative HAD of the same patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes comparison of the connectivity of OP3 explored by functional Magnetic Resonance Imaging (fMRI) at 1.5 T.</measure>
    <time_frame>15 months</time_frame>
    <description>Functional Magnetic Resonance Imaging records (fMRI 1.5 T) performed preoperatively and at 15 months postoperatively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Connectivities changes of the right OP3 measured by magnetoencephalography (MEG) at baseline 'preoperatively) and the post op (within 1 week) and at long term follow up (15 months) with active stimulation (ON) and inactive (OFF) during MEG recording.</measure>
    <time_frame>15 months</time_frame>
    <description>Magnetoencephalography (MEG) records at baseline (preoperatively) and the post op (within 1 week) and at long term follow up (15 months) with active stimulation (ON) and inactive (OFF) during MEG recording.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterization of the Local Field Potential (LFP) recorded and correlations with tinnitus features perceived by the patient, based on their intensity and characteristic.</measure>
    <time_frame>One week</time_frame>
    <description>Local Field Potential (LFP) records on the electrode when the patient perceives tinnitus features 1) intraoperatively 2) before the implantation of the stimulator.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">7</enrollment>
  <condition>Severe Permanent Uni or Bilateral Non-pulsatile Tinnitus</condition>
  <condition>Without Associated Vestibular Pathology</condition>
  <condition>Resistant to Therapeutic Failure</condition>
  <condition>With or Without Hearing Loss</condition>
  <arm_group>
    <arm_group_label>Deep Brain Stimulation (DBS) activated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with severe permanent non-pulsatile tinnitus treated by Deep Brain Stimulation (DBS) in position ON</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Deep Brain Stimulation (DBS) non-activated</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with severe permanent non-pulsatile tinnitus treated by Deep Brain Stimulation (DBS) in position OFF</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DBS</intervention_name>
    <description>Deep Brain Stimulation (DBS) of the parieto-insular region at the level of the right operculum 3 (OP3)</description>
    <arm_group_label>Deep Brain Stimulation (DBS) activated</arm_group_label>
    <arm_group_label>Deep Brain Stimulation (DBS) non-activated</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Between 18 and 75 years old,

          2. Uni or bilateral permanent non-pulsatile tinnitus, without associated vestibular
             pathology, with or without hearing loss,

          3. Severe tinnitus resistant to treatment failure,

          4. Tinnitus intensity on the Visual Analog Scale (VAS) ≥ 7,

          5. Presenting a quality of life score on the Tinnitus Handicap Inventory (THI)
             questionnaire&gt; 76 (= grade 5),

          6. Social security affiliates or beneficiaries of such a scheme

          7. Informed and written consent signed by the patient.

        Exclusion Criteria:

          1. Vestibular dysfunction (balance disorder),

          2. Epilepsy,

          3. Intercurrent serious pathology,

          4. Brain tumor,

          5. Contraindication to surgery or anesthesia,

          6. History of cerebral infection with herpesvirus,

          7. With a contraindication to the practice of MRI, MEG, Computerized Tomography (CT)
             scan,

          8. Under anticoagulants and antiaggregants (Anti vitamin K, low molecular weight heparin,
             aspirin and derivatives, clopidogrel antiplatelet agents and assimilated, new oral
             anticoagulants (NACO)) for which a therapeutic window can not be opened within 3
             months before and after the surgery,

          9. Included in another therapeutic protocol,

         10. Progressive dementia or psychiatric illness,

         11. Presenting a suicidal risk deemed important for less than 3 months (Montgomery and
             Asberg depression scale (MADRS): suicidality item (item 10) score&gt; 2),

         12. Enforced hospitalisation,

         13. Pregnant, parturient or breastfeeding, lack of contraception in patients with the
             capacity to procreate,

         14. Subject to a legal protection measure,

         15. Deprived of liberty by judicial or administrative decision,

         16. Isolated patient without any contact in case of emergency.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Stéphan CHABARDES, MD, PhD</last_name>
    <phone>33 (0)4 76 76 93 85</phone>
    <email>SChabardes@chu-grenoble.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Caroline SANDRE-BALLESTER, PhD</last_name>
    <phone>33 (0)4 38 78 28 51</phone>
    <email>CSandreballester@chu-grenoble.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CLINATEC</name>
      <address>
        <city>Grenoble</city>
        <zip>38000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Stephan CHABARDES, MD, PhD</last_name>
      <phone>33 (0)4 76 76 93 85</phone>
      <email>SChabardes@chu-grenoble.fr</email>
    </contact>
    <contact_backup>
      <last_name>Caroline SANDRE-BALLESTER, PhD</last_name>
      <phone>33 (0)4 38 78 28 51</phone>
      <email>CSandreballester@chu-grenoble.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Eric SEIGNEURET, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Job A, Paucod JC, O'Beirne GA, Delon-Martin C. Cortical representation of tympanic membrane movements due to pressure variation: an fMRI study. Hum Brain Mapp. 2011 May;32(5):744-9. doi: 10.1002/hbm.21063.</citation>
    <PMID>21484948</PMID>
  </reference>
  <reference>
    <citation>Job A, Pons Y, Lamalle L, Jaillard A, Buck K, Segebarth C, Delon-Martin C. Abnormal cortical sensorimotor activity during &quot;Target&quot; sound detection in subjects with acute acoustic trauma sequelae: an fMRI study. Brain Behav. 2012 Mar;2(2):187-99. doi: 10.1002/brb3.21.</citation>
    <PMID>22574285</PMID>
  </reference>
  <reference>
    <citation>Job A, Jacob R, Pons Y, Raynal M, Kossowski M, Gauthier J, Lombard B, Delon-Martin C. Specific activation of operculum 3 (OP3) brain region during provoked tinnitus-related phantom auditory perceptions in humans. Brain Struct Funct. 2016 Mar;221(2):913-22. doi: 10.1007/s00429-014-0944-0. Epub 2014 Dec 12.</citation>
    <PMID>25503643</PMID>
  </reference>
  <reference>
    <citation>Eickhoff SB, Grefkes C, Zilles K, Fink GR. The somatotopic organization of cytoarchitectonic areas on the human parietal operculum. Cereb Cortex. 2007 Aug;17(8):1800-11. Epub 2006 Oct 10.</citation>
    <PMID>17032710</PMID>
  </reference>
  <reference>
    <citation>Mălîia MD, Donos C, Barborica A, Popa I, Ciurea J, Cinatti S, Mîndruţă I. Functional mapping and effective connectivity of the human operculum. Cortex. 2018 Dec;109:303-321. doi: 10.1016/j.cortex.2018.08.024. Epub 2018 Sep 10.</citation>
    <PMID>30414541</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 24, 2020</study_first_submitted>
  <study_first_submitted_qc>March 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2020</study_first_posted>
  <last_update_submitted>March 2, 2020</last_update_submitted>
  <last_update_submitted_qc>March 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tinnitus</keyword>
  <keyword>Deep Brain Stimulation (DBS)</keyword>
  <keyword>Right operculum 3 (OP3)</keyword>
  <keyword>Functional Magnetic Resonance Imaging (fMRI)</keyword>
  <keyword>Magnetoencephalography (MEG)</keyword>
  <keyword>Local Field Potential (LFP)</keyword>
  <keyword>Visual Analog Scale (VAS)</keyword>
  <keyword>Tinnitus Handicap Inventory (THI) questionnaire</keyword>
  <keyword>Hospital Anxiety and Depression Scale (HAD)</keyword>
  <keyword>Cross-over study</keyword>
  <keyword>Double blind design</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hearing Loss</mesh_term>
    <mesh_term>Tinnitus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

